Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
regulatory affairs
Biotech
ProJenX ALS drug gets back on the map after partial FDA hold
ProJenX is back on the map after the FDA lifted a partial clinical hold on a phase 1 clinical trial for an amyotrophic lateral sclerosis drug.
Annalee Armstrong
Mar 29, 2024 10:44am
FDA releases final CAR-T guidelines amid separate safety probe
Jan 29, 2024 11:41am
Innate secures speedy resolution of FDA hold on lymphoma trials
Jan 4, 2024 9:50am
AbbVie CEO Gonzalez brushes off FTC concerns for Cerevel buy
Dec 7, 2023 11:26am
Karuna's schizophrenia drug set for FDA decision in Q3 2024
Nov 29, 2023 10:00am
Mersana's phase 1 ADC cancer trial breaks free of FDA hold
Oct 31, 2023 1:21pm